- Home
- POCI vs BCAB Comparison
POCI vs BCAB Comparison
Compare POCI & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POCI
- BCAB
- Stock Information
- Founded
- POCI 1982
- BCAB 2007
- Country
- POCI United States
- BCAB United States
- Employees
- POCI N/A
- BCAB N/A
- Industry
- POCI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- POCI Health Care
- BCAB Health Care
- Exchange
- POCI Nasdaq
- BCAB Nasdaq
- Market Cap
- POCI 32.4M
- BCAB 27.0M
- IPO Year
- POCI N/A
- BCAB 2020
- Fundamental
- Price
- POCI $4.21
- BCAB $0.41
- Analyst Decision
- POCI
- BCAB Buy
- Analyst Count
- POCI 0
- BCAB 2
- Target Price
- POCI N/A
- BCAB $5.00
- AVG Volume (30 Days)
- POCI 7.6K
- BCAB 834.0K
- Earning Date
- POCI 02-13-2025
- BCAB 03-25-2025
- Dividend Yield
- POCI N/A
- BCAB N/A
- EPS Growth
- POCI N/A
- BCAB N/A
- EPS
- POCI N/A
- BCAB N/A
- Revenue
- POCI $18,682,766.00
- BCAB $11,000,000.00
- Revenue This Year
- POCI N/A
- BCAB N/A
- Revenue Next Year
- POCI N/A
- BCAB N/A
- P/E Ratio
- POCI N/A
- BCAB N/A
- Revenue Growth
- POCI N/A
- BCAB N/A
- 52 Week Low
- POCI $3.47
- BCAB $0.38
- 52 Week High
- POCI $6.90
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- POCI 24.49
- BCAB 32.49
- Support Level
- POCI $4.75
- BCAB $0.42
- Resistance Level
- POCI $5.04
- BCAB $0.50
- Average True Range (ATR)
- POCI 0.25
- BCAB 0.05
- MACD
- POCI -0.08
- BCAB 0.02
- Stochastic Oscillator
- POCI 0.00
- BCAB 20.97
About POCI Precision Optics Corporation Inc.
Precision Optics Corp Inc is engaged in designing, developing, and manufacturing advanced optical instruments. It manufactures medical products such as endoscopes and endocouplers which incorporate various optical technologies for use in a variety of minimally invasive surgical and diagnostic procedures. The company also produces endoscopes for various applications as well as designs and manufactures custom optical medical devices to satisfy customers' specific requirements. In addition, the company manufactures and sells components and assemblies specially designed for industrial and military use. The company earns the majority of its revenue from the United States.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.